Goldman Sachs
NMRA icon

Goldman Sachs’s Neumora Therapeutics NMRA Stock Holding History

Goldman Sachs’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Sell
303,862
-264,418
-47% -$503K ﹤0.01% 5679
2026
Q1 		$1.11M Sell
568,280
-290,222
-34% -$752K ﹤0.01% 5029
2025
Q4 		$1.54M Buy
858,502
+481,128
+127% +$1.05M ﹤0.01% 4810
2025
Q3 		$687K Sell
377,374
-124,795
-25% -$202K ﹤0.01% 5308
2025
Q2 		$368K Sell
502,169
-105,615
-17% -$80K ﹤0.01% 5334
2025
Q1 		$608K Sell
607,784
-33,139
-5% -$56.7K ﹤0.01% 5066
2024
Q4 		$6.79M Buy
640,923
+300,902
+88% +$3.61M ﹤0.01% 3148
2024
Q3 		$4.49M Buy
340,021
+21,564
+7% +$252K ﹤0.01% 3443
2024
Q2 		$3.13M Buy
318,457
+155,878
+96% +$1.61M ﹤0.01% 3579
2024
Q1 		$2.24M Sell
162,579
-429,843
-73% -$6.95M ﹤0.01% 3790
2023
Q4 		$10.1M Buy
592,422
+518,822
+705% +$6.37M ﹤0.01% 2517
2023
Q3 		$1.04M Buy
+73,600
New +$920K ﹤0.01% 4246

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's NMRA Position: Q2 2026 in Review

Goldman Sachs reduced its Neumora Therapeutics (NMRA) stake by 47% in Q2 2026, selling an estimated $503K and leaving 303,862 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #5679.

Goldman Sachs first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $10.1M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Goldman Sachs held 303,862 shares of Neumora Therapeutics worth $517K as of Q2 2026.
  • Goldman Sachs sold 264,418 Neumora Therapeutics shares in Q2 2026, an estimated $503K.
  • Neumora Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5679 holding.
  • Goldman Sachs first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Goldman Sachs's Neumora Therapeutics position peaked at $10.1M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.